Results 281 to 290 of about 3,106,146 (396)

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1999
Lihao Meng   +5 more
semanticscholar   +1 more source

Xanthatin Targets CISD1 to Drive Ferroptosis and Mitophagy as a Dual Anticancer Strategy in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Triple‐negative breast cancer has a poor prognosis. Xanthatin directly targets and degrades CISD1, triggering ferroptosis through iron dysregulation. The concurrently activated mitophagy synergistically amplifies ferroptotic cell death. Xanthatin also demonstrates potent in vivo anti‐tumor efficacy with minimal toxicity, highlighting its therapeutic ...
Qinwen Liu   +9 more
wiley   +1 more source

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma. [PDF]

open access: yesCancer Med
Tang W   +12 more
europepmc   +1 more source

Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress

open access: yesAntioxidants and Redox Signaling, 2014
Slavica Brnjic   +7 more
semanticscholar   +1 more source

Gut Microbe‐Driven Resistance Mechanisms in Propylea Japonica: Insights from Horizontal Gene Transfer and Oxidative Phosphorylation

open access: yesAdvanced Science, EarlyView.
Acinetobacter regulates dinotefuran tolerance in Propylea japonica by mediating the expression of the horizontally transferred gene PjDUF1. Abstract Insect–microbial symbiont relationships are widespread in nature and often involve lateral gene transfer.
Ningbo HuangFu   +10 more
wiley   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao   +10 more
wiley   +1 more source

miR-326 overexpression inhibits colorectal cancer cell growth and proteasome activity by targeting PNO1: unveiling a novel therapeutic intervention strategy [PDF]

open access: gold
Yi Fang   +15 more
openalex   +1 more source

Home - About - Disclaimer - Privacy